# Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

> **NCT02181985** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 5989 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** Full dose TNK-tPA
- **DRUG:** Half dose TNK-tPA
- **DRUG:** Heparin
- **DRUG:** Enoxaparin
- **DRUG:** Abciximab

## Key facts

- **NCT ID:** NCT02181985
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2001-04
- **Final completion:** —
- **Target enrollment:** 5989 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181985, "Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02181985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*